How it works:
Lenalidomide, a derivative of thalidomide, exhibits potent immunomodulatory, antitumour, and anti-angiogenic properties. It enhances T-cell and NK-cell activation, inhibits tumour growth, and reduces abnormal blood vessel formation. It is used in monotherapy or in combination with other agents, particularly for multiple myeloma treatment.
Recommended for:
Patients with multiple myeloma
Individuals with myelodysplastic syndromes with 5q deletion
Patients with relapsed/refractory mantle cell lymphoma
Those requiring post-transplant maintenance therapy
Cases where conventional treatment failed
Multiple myeloma
Myelodysplastic syndromes with 5q deletion
Mantle cell lymphoma
Maintenance therapy after stem cell transplantation
Lenalidomide is taken orally once daily with water, at the same time each day. Dosage and duration are determined by a healthcare professional, depending on the type and stage of disease. Regular blood and liver monitoring is essential during therapy.
Hypersensitivity to lenalidomide
Pregnancy and breastfeeding
History of thromboembolic events
Severe renal impairment without dose adjustment
Mental health disorders including depression
Anaemia, neutropenia, thrombocytopenia
Constipation, diarrhoea, nausea
Fatigue, insomnia
Skin rash, itching
Increased risk of venous thrombosis
Elevated risk of infections
